Enabling the discovery and development of AKT inhibitors as novel cancer therapeutics
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 5 - Biological Sciences
- Summary impact type
- Technological
- Request cross-referral to
- -
- Is this case study continued from a case study submitted in 2014?
- Yes
3. References to the research
5. Sources to corroborate the impact
Additional contextual information
Grant funding
Grant number |
Value of grant |
C309/A2187 |
£22,500,000 |
95/A3/B/00415 |
£30,553 |
C576/A25 |
£1,498,807 |
C309/A8274 |
£29,156,418 |
- Countries
-
- UK
- Netherlands
- Argentina
- Australia
- Belgium
- Canada
- China
- France
- Germany
- Hungary
- Israel
- Italy
- Japan
- South Korea
- Peru
- Poland
- Russia
- Spain
- Taiwan
- Brazil
- Colombia
- Czechia
- Greece
- India
- Mexico
- Philippines
- Portugal
- Saudi Arabia
- South Africa
- Sweden
- Thailand
- Turkey
- Vietnam
- Austria
- Bulgaria
- Chile
- Slovakia
- Switzerland
- Formal partners
-
- Friedrich Miescher Institute
- Astex
- AstraZeneca
- Funding programmes
-
- Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2001 to 2006)
- Biotechnology and Biological Sciences Research Council: Structural and functional studies of SH2 domain-containing protein tyrosine phosphatases (Studentship)
- Cancer Research UK: Molecular Basis for Control
- Cancer Research UK: Cancer Therapeutics Unit (CTU) grant (2006 to 2011)
- Global research identifiers
-
- grid.11485.39
- grid.418100.c
- Name of funders
-
- Cancer Research UK
- Biotechnology and Biological Sciences Research Council
- Researcher ORCIDs
-
- 0000-0001-8810-950X
- 0000-0003-1659-3034
- 0000-0002-3939-1673
- 0000-0002-8143-8498
- 0000-0003-1503-3123
- 0000-0001-8937-0873